BACKGROUND: Health care workers (HCW) such as anesthesiologists, surgeons, and intensivists face high rates of exposure to SARS-CoV-2 through direct contact with COVID-19 patients. While there are initial reports of the prevalence of COVID-19 antibodies among the general population, there are few reports comparing the seroprevalence of IgM/IgG COVID-19 antibodies in HCW of different exposure levels as well as different HCW professions. METHODS: A convenience sample of health care workers provided blood for COVID-19 antibody testing and a review of medical history and work exposure for correlative analyses. RESULTS: Overall, 474 HCW were enrolled in April 2020 including 102 front-line physicians (e.g., anesthesiologists, surgeons, intensivists, emergency medicine), 91 other physicians, 135 nurses, 134 other clinical staff, and 12 non-clinical HCW. The prevalence of IgM or IgG antibodies to SARS-CoV-2 was 16.9% (95% CI 13.6-20.6) (80/474). The proportion of positive antibodies in the PCR + group was significantly higher than health care workers without symptoms (84.6% [95% CI 54.6-98.1] vs. 12.3% [95% CI 8.5-17.2], p < 0.001). No significant differences in proportions of COVID-19 antibodies were observed among the different exposure groups (e.g., high vs minimal/no exposure) and among the different HCW professionals. CONCLUSIONS: Despite exposure to COVID-19 patients, the prevalence of antibodies in our HCW was similar to what has been reported for the general population of New York State (14%) and for another New York HCW cohort (13.7%). Health care workers with higher exposure rates were not more likely to have been infected with COVID-19. Therefore, these data suggest that infection of HCW may result from exposure in the community rather than at work. TRIAL REGISTRATION: This investigator-initiated study was observational; therefore, no registration was required. Not applicable.
BACKGROUND: Health care workers (HCW) such as anesthesiologists, surgeons, and intensivists face high rates of exposure to SARS-CoV-2 through direct contact with COVID-19 patients. While there are initial reports of the prevalence of COVID-19 antibodies among the general population, there are few reports comparing the seroprevalence of IgM/IgG COVID-19 antibodies in HCW of different exposure levels as well as different HCW professions. METHODS: A convenience sample of health care workers provided blood for COVID-19 antibody testing and a review of medical history and work exposure for correlative analyses. RESULTS: Overall, 474 HCW were enrolled in April 2020 including 102 front-line physicians (e.g., anesthesiologists, surgeons, intensivists, emergency medicine), 91 other physicians, 135 nurses, 134 other clinical staff, and 12 non-clinical HCW. The prevalence of IgM or IgG antibodies to SARS-CoV-2 was 16.9% (95% CI 13.6-20.6) (80/474). The proportion of positive antibodies in the PCR + group was significantly higher than health care workers without symptoms (84.6% [95% CI 54.6-98.1] vs. 12.3% [95% CI 8.5-17.2], p < 0.001). No significant differences in proportions of COVID-19 antibodies were observed among the different exposure groups (e.g., high vs minimal/no exposure) and among the different HCW professionals. CONCLUSIONS: Despite exposure to COVID-19 patients, the prevalence of antibodies in our HCW was similar to what has been reported for the general population of New York State (14%) and for another New York HCW cohort (13.7%). Health care workers with higher exposure rates were not more likely to have been infected with COVID-19. Therefore, these data suggest that infection of HCW may result from exposure in the community rather than at work. TRIAL REGISTRATION: This investigator-initiated study was observational; therefore, no registration was required. Not applicable.
Entities:
Keywords:
COVID-19; Health care worker; Humoral immunity; Intensivist; SARS-CoV-2
Authors: Joseph Moscola; Grace Sembajwe; Mark Jarrett; Bruce Farber; Tylis Chang; Thomas McGinn; Karina W Davidson Journal: JAMA Date: 2020-09-01 Impact factor: 56.272
Authors: Eli S Rosenberg; James M Tesoriero; Elizabeth M Rosenthal; Rakkoo Chung; Meredith A Barranco; Linda M Styer; Monica M Parker; Shu-Yin John Leung; Johanne E Morne; Danielle Greene; David R Holtgrave; Dina Hoefer; Jessica Kumar; Tomoko Udo; Brad Hutton; Howard A Zucker Journal: Ann Epidemiol Date: 2020-06-17 Impact factor: 3.797
Authors: Emily E Wiemers; Scott Abrahams; Marwa AlFakhri; V Joseph Hotz; Robert F Schoeni; Judith A Seltzer Journal: Res Soc Stratif Mobil Date: 2020-09-07
Authors: Dennis J Baumgardner; Alexander Schwank; Jessica J F Kram; Wilhelm Lehmann; Jacob L Bidwell; Tricia La Fratta; Kenneth Copeland Journal: J Patient Cent Res Rev Date: 2022-01-17
Authors: Cédric Hirzel; Alexia Cusini; Katarzyna Szajek; Felix Fleisch; Sandra Hutter; Martin Risch; Theresa Bechmann; Valerie A Luyckx; Sabine Güsewell; Amico Study Group Journal: Antimicrob Resist Infect Control Date: 2022-01-10 Impact factor: 4.887
Authors: Eli D Ehrenpreis; Sigrun Hallmeyer; David H Kruchko; Alexea A Resner; Nhan Dang; Natasha Shah; Nancy Mayer; Anne Rivelli Journal: Healthcare (Basel) Date: 2022-02-01